Dramatic Survival Benefit with Nivolumab in Melanoma.
In a phase I study of nivolumab in patients with advanced, metastatic melanoma, 34% are still alive 5 years later, a survival rate twice what was typical when the study began in 2008.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000401:mortality*; D058990:Molecular Targeted Therapy; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab